PHARMAC
TE PĀTAKA WHAIORANGA

Pharmacology and Therapeutics
Advisory Committee

Objective advice to Pharmac

Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand
www.pharmac.govt.nz

PTAC Provisional recommendations from meeting held 15 & 16 May 2025

Pharmac is piloting a new approach which will allow people to understand the advice we get within 30 business days of advisory committee meetings. More information about provisional recommendations is on the Pharmac website here: https://www.pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Foslevodopa / foscarbidopa (branded as Vyalev) for people with advanced Parkinson's disease, subject to Special Authority criteria	Medium priority
Etonogestrel subdermal implant (branded as Implanon NXT) for contraception	Withheld*
Vanzacaftor, tezacaftor, deutivacaftor for the treatment of cystic fibrosis in people aged six years and older with a non-F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene responsive only to vanzacaftor, tezacaftor, deutivacaftor (non-F/VNZ-responsive), subject to Special Authority criteria	High Priority
Vanzacaftor, tezacaftor, deutivacaftor for the treatment of cystic fibrosis in people aged six years and over with F508del mutation(s) or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene responsive to Trikafta (elexacaftor, tezacaftor, ivacaftor (non-F/ETI-responsive), subject to Special Authority criteria.	Cost Neutral to currently funded Trikafta
Secukinumab (branded as Cosentyx) as a first line biologic for moderate to severe hidradenitis suppurativa	Declined
Secukinumab as a second line biologic for moderate to severe hidradenitis suppurativa, subject to Special Authority criteria	High Priority
Sacituzumab govitecan for triple negative, locally advanced or metastatic breast cancer, subject to Special Authority criteria	Withheld*
Durvalumab (branded as Imfinzi) for the treatment of extensive-stage small cell lung cancer, subject to Special Authority criteria	High Priority

*Withheld provisional recommendation – the applicant / supplier has requested the recommendation not be released until full record is available.

More information about the agenda items considered at the recent PTAC meeting can be found on the Pharmac website here: https://www.pharmac.govt.nz/news-and-resources/news/agenda-for-may-2025-pharmacology-and-therapeutics-advisory-committee-ptac-meeting.